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Inflammatory markers are increased systematically and locally (e.g., skeletal muscle) in stroke patients. Besides being associated
with cardiovascular risk factors, proinflammatory cytokines seem to play a key role in muscle atrophy by regulating the pathways
involved in this condition. As such, they may cause severe decrease in muscle strength and power, as well as impairment in
cardiorespiratory fitness. On the other hand, physical exercise (PE) has been widely suggested as a powerful tool for treating stroke
patients, since PE is able to regenerate, even if partially, physical and cognitive functions. However, the mechanisms underlying the
beneficial effects of physical exercise in poststroke patients remain poorly understood.Thus, in this study we analyze the candidate
mechanisms associated with muscle atrophy in stroke patients, as well as the modulatory effect of inflammation in this condition.
Later, we suggest the two strongest anti-inflammatory candidate mechanisms, myokines and the cholinergic anti-inflammatory
pathway, which may be activated by physical exercise and may contribute to a decrease in proinflammatory markers of poststroke
patients.
1. Introduction
Chronic stroke is the second leading cause of death and the
third cause of disability worldwide. Moreover, the overall
incidence of stroke is increasing exponentially. From 1990
to 2010, the number of deaths and disabilities related with
stroke rose by 26% and 19%, respectively, regardless of the age
group [1, 2]. Indeed, every year approximately 795,000 people
experience a new or recurrent chronic stroke, and every four
minutes someone dies from stroke in the United States [3].
Furthermore, it has been shown that stroke prevalence
is greater in low-income countries when compared to devel-
oped countries. A systematic review comprising 56 epidemi-
ological studies carried out between 1970 and 2008 showed
that in ten countries of low and middle income the incidence
and premature mortality due to chronic stroke more than
doubled, reaching 5.6% increase annually [4].
Muscle atrophy in the paretic and nonparetic limbs is a
phenotypic change caused by different factors (e.g., hemi-
paresis and immobilization) observed in poststroke patients
[5]. Since this atrophy is associated with decrease in muscle
strength and power, cardiovascular fitness, and mobility,
some researchers have suggested that poststroke patients
show stroke-related sarcopenia, similar to the muscle weak-
ness found in elderly people [6, 7]. Regardless of the molec-
ular pathway responsible for eliciting this phenomenon,
several studies have indicated that increased inflammatory
markers may be a trigger factor for this condition [8, 9]. In
fact, some findings from research have pointed that proin-
flammatory cytokines (e.g., TNF-𝛼 and IL-6) may activate
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the molecular pathways involved muscle atrophy (e.g., ubiq-
uitin proteasome system).
On the other hand, physical exercise has been widely
suggested as a beneficial tool for rehabilitation of stroke
patients, since it may be able to counterregulate most of the
stroke sequelae on the organic system [10]. Indeed, several
reviews have suggested that physical exercise may elicit
improvement on cognition, upper and lower limb motor
function, cardiovascular performance, cardiovascular risk
factors (e.g., triglycerides and insulin resistance), fatigue
resistance, balance, gait, and mobility [10–12]. Also, physical
exercise has been effectively used as an anti-inflammatory
therapy in chronic diseases [13–16].
Unfortunately, data about the mechanisms underlying
the beneficial effects of physical exercise on poststroke
patients are limited. However, several experiments have
already demonstrated that physical exercise may decrease the
inflammatory state through myokines and the cholinergic
anti-inflammatory pathway; as such, wemay hypothesize that
both mechanisms may also be present in stroke patients. In
this sense, the present study attempted to demonstrate the
potential role of inflammation on muscle atrophy, regardless
of specific molecular pathways in poststroke patients. We
also assessed the compensatory role of myokines and the
cholinergic anti-inflammatory pathway in counterbalancing
this phenomenon and consequently improving prognosis.
2. Functional and Skeletal Muscle
Complications Associated with Stroke
Stroke complications are numerous and variable depending
on the site of impairment and the degree of obstruction of
the blood vessels involved. Generally, stroke complications
may be characterized as morphological (e.g., decrease in
muscle mass and increase in muscle mass fat infiltration),
physical (e.g., hemiparesis, spasticity, rigidity, balance and
coordination changes, tremors, deficit in gross and finemotor
skills, and sensory changes), psychoaffective (e.g., depressive
disorders, anxiety, and aggressiveness), and cognitive (mem-
ory, attention, and concentration issues, language disorders
and executive functions, difficulty in action planning, and
perceptual deficit) [6, 7, 17].
Regarding physical alterations, hemiparesis or muscle
weakness contralateral to brain lesion, which is characterized
byweakness/palsy in one of the sagittal body sides and central
nervous system injury, is the most frequent disability found
in poststroke patients, affecting around 50% of the patients
[6, 18–21].
Hemiparesis is closely associated with muscular abnor-
malities, which, in turn, cause impairment in muscle func-
tionality [6, 18]. Indeed, studies have found poststroke atro-
phy in the contralateral limb,whereas results on the ipsilateral
limb have demonstrating maintaining or even trend to
increase in the muscle mass [20, 22, 23]. Moreover, evidences
demonstrate nondifferences between the muscle volume of
the quadriceps from the ipsilateral limb of poststroke patients
in comparison with the limb of control groupmatched by age
and sex [23]. In the following 3months after a stroke, patients
show small differences in muscle mass content between
the contralateral and ipsilateral limb with women and men
displaying 1.88% and 3.74% lower muscle mass in the paretic
limb and nonparetic limb, respectively [22]. However, with
the progression of the condition, differences between sagittal
sides may amount to 24% in 6 months [20, 23].
In line with these findings, a systematic review, which
evaluated 14 studies, undertaken in three different continents
(i.e., America, Europe, and Asia) and involved 450 poststroke
patients (i.e., 53.5–75 years), has shown that the contralateral
limb displayed 4.5% atrophywhen compared to the ipsilateral
limb, with a high magnitude of atrophy observed in the
midthigh (14.5%) [5].
Decrease inmuscle mass due hospitalization is associated
with poor prognosis, including length of stay in intensive care
unit in different population [24, 25]. In poststroke patients,
decrease in muscle mass few days after the phenomenon is
associated with impairment in the capacity to walk again
[26]. Furthermore, evidence suggests that this association is
dependent on the affected limb, as demonstrated by Prado-
Medeiros et al. [23], who found a moderate but significantly
negative association between paretic limb atrophy (but not
in ipsilateral limb) and the capacity to generate strength and
power of the muscle knee flexors and extensors [23].
The paretic limb shows lower isometric and isotonic
strength than ipsilateral limb [20, 27]; in turn, both show
lower strength than nonaffected healthy control limbs [27].
These physical characteristics involved in the capacity to
generate strength and power in poststroke patients deserve
attention, since low strength is positively associated with low
scores in tests that mimic the activities of daily life (ADL),
such as six-minute walk test (6MWT), stair climbing (i.e.,
normal and fast pace), gait speed (i.e., normal and fast pace),
moving from a sitting to a standing position, flexing the
affected knee, and scales, which evaluate muscle function
(i.e., Rivermead motor assessment), in poststroke patients
[23, 28, 29]. Moreover, patients who suffered stroke seem to
spend more energy to perform these daily tasks [29].
Due these stroke-induced alterations on muscle mass,
physical function, and functionality, some studies have sug-
gested that the term sarcopenia should be employed to
describe this phenotype found in poststroke patients [6, 7].
According to the these investigations, this aspect is clinically
important since sarcopenia has been found to be a trigger
factor to development of syndromes associated with low
resilience in elderly people, such as frailty syndrome [30].
However, muscle and functional alterations in poststroke
patients seems to occur in different times and magnitudes,
unlike the changes observed in elderly people [6, 7, 18, 31].
Muscle fiber shifting helps explain these differences. In
older people, predominantly, histological analyses show type
II fast-twitch shift toward to type I low-twitch muscle fibers
[32, 33]. On the other hand, poststroke patients undergo
an inverse phenomenon, whereby type I low-twitch muscle
fibers shift forward to type II fast-twitch muscle fibers [6, 18].
These histological changes are inversely associated with gait
speed and are likely to be caused by altered neural activation
patterns [34]. However, consensus about sarcopenia diagno-
sis in poststroke patients has not yet been reached, as well as
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the role it plays in the physical function in this population
[6, 7, 19].
3. Possible Mechanisms Associated with
Muscle Atrophy in Poststroke Patients
Some mechanisms have been suggested to explain muscle
atrophy in poststroke patients [6, 7]; however, little is known
about them [6, 7]. Muscle atrophy is caused by an imbalance
between protein synthesis and breakdown and can be elicited
by two phenomena: (a) when the rate of protein breakdown
(i.e., proteolysis) exceeds the rate of protein synthesis and (b)
when the rate of protein synthesis decreases [35, 36].
The insulin-like growth factor 1 (IGF-1)/Akt/mammalian
target of rapamycin (mTOR) pathway (i.e., IGF-1/Akt/
mTOR) has been known to be the most important pathway
to muscle protein synthesis [36].
IGF-1 is a circulating growth factor synthesized in differ-
ent tissues, including the skeletal muscle [37, 38]. IGF-1 may
act either as a hormone, due to its systemic characteristic, or
in an autocrine fashion, as a local growth factor [38]. Activity
of IGF-1 on skeletal muscle is a strong stimulus to muscle
hypertrophy [38, 39]. Indeed, a transgenic mice model with
overexpressing of IGF-1 gene has shown higher muscle mass
in fore and hind limbs, due to increase in the muscle cross-
sectional area of type II fibers, during adult life and older age,
in comparison with the wild type [38].
The activity of IGF-1 ismediated by its binding to tyrosine
kinase IGF-1 receptor in the lipid bilayer [36, 40, 41]. IGF-
1 recruits insulin receptor substrate (IRS-1), which is also
activated by insulin and, consequently, leads to the phos-
phorylation and activation of phosphatidylinositol 3-kinase
(PI3K) [36, 40]. PI3K phosphorylates phosphatidylinositol
(4, 5) bisphosphate, synthetizing phosphatidylinositol (3, 4,
5) [36, 39–41]. This process allows the creation of a lipid-
binding site to Akt [36, 39–41]. Downstream targets of Akt
are the mammalian target of rapamycin (mTOR), which, in
turn, phosphorylates and activates p70s6k, also called S6K1,
through the essential regulatory subunit eIF3f, ribosomal
proteins, which eventually leads to increased ribosomal
biogenesis and protein translation [41–44]. Still regarding
eIF3f, this regulatory subunit acts as a scaffold, allowing
the activation of mTOR downstream targets (i.e., p70S6K)
[42]. This phenomenon occurs from the binding of mTOR
on C-terminal of the eIF3f subunit, phosphorylating and
activating p70S6K, which is found anchored in the mov34
domain [42]. Evidences indicate that increase of MAFbx
in response to food deprivation causes eIF3f loss, leading
to marked decrease on phosphorylation of p70S6K, without
alterations in mTOR activity, indicating the association of
mTOR downstream targets [42]. On the other hand, over-
expression of eIF3 subunit elicits significantly an increase
in P70S6K [42]. It is important to mention that 4E-BP1, a
dual activity molecule, can be a key factor in muscle mass
regulation, since its molecule can activate eIF3f, after be
phosphorylate by mTOR, which leads to its dissociation of
eIF3f [45]. However, eIF3f inactivation can occur if 4E-BP1 is
dephosphorylated [45].
Moreover, results from experiments in vitro and in vivo
have demonstrated that IGF-1/PI3K/Akt/mTOR pathway
may revert muscle proteolysis andmuscle myofibrillar break-
down (i.e., actinin), by inhibiting E3 ligases (i.e., MAFbx and
MuRF-1), FoxO1—which also activates MAFbx and MuRF-
1—, and decrease in the activity of the ubiquitin proteasome
system [36, 37, 39, 46].
In an animal model of stroke, atrophied paretic and
nonparetic muscles show a downregulation of the IGF-
1/PI3K/Akt/mTOR pathway [47]. In poststroke patients, few
studies have focused on the association between IGF-1 and
muscle atrophy [48]. In the studied performed by Silva-Couto
et al. [48], chronic stroke patients with hemiparesis showed
lower serum concentrations of IGF-1 and IGFB-3, an IGF-
1 transporter, than healthy controls. Concomitantly, muscle
atrophy was found in poststroke patients [48]. Other studies
have shown a positive correlation between muscle function
and IGF-1 serum concentrations, which may indicate a
modulation by muscle mass [49]. However, this variable was
not measured.Therefore, inferences about the IGF-1 pathway
onmuscle atrophy in poststroke patients are still sensitive and
we must be proceeding with caution.
There is more considerable evidence in the literature
for muscle atrophy elicited by the increased rate of protein
breakdown than by protein synthesis.
As aforementioned, muscle atrophy is one of the com-
ponents of the poststroke phenotype [6, 7, 18]. Besides
the contribution of hemiparesis to this phenomenon, bed
rest time, which occurs from one to three days after the
event, immobilization, and decrease in physical activity levels
negatively affectmuscular homeostasis in poststroke patients,
leading tomuscle atrophy due to denervation, unloading, and
disuse [7, 26, 50].
Although disuse atrophy is probably not regulated by
a single mechanism, but a complex one [36], the ATP-
dependent ubiquitin proteasome system (UPS) has been
widely suggested as the main mechanism responsible for
muscle atrophy, since UPS genes were found to be increased
inmuscular atrophy due to different factors (i.e., denervation,
unloading, and disuse) [36, 37, 40, 43]. Ubiquitin is a
small peptide that targets the protein, leading to ubiquitin-
dependent protein catabolism and forming the core of amuch
larger protease, the 26S proteasome [40, 43]. The process of
ubiquitination, protein labeling and targeting, is dependent
on three ubiquitin-enzymes: E1 ubiquitin-activating enzyme,
an E2 ubiquitin-conjugating enzyme, and an E3 ubiquitin-
ligating enzyme [36, 40]. These enzymes act in a chain reac-
tion fashion creating a polyubiquitination chain, where E1
activates, through an ATP-dependent pathway, and transfers
the ubiquitin to E2, which is later replaced by E3 [36, 37, 40,
51], which, in turn, catalyzes the conjugation of the ubiquitin
with the target protein [40, 51].
In the skeletal muscle, two muscle-specific E3 enzymes
have been studied and were found to be associated with the
muscle atrophy phenotype [36, 37, 40]. Muscle ringer finger
1 (MuRF1) and muscle atrophy F-box (MAFbx), also called
Atrogin-1, are two E3 ligases widely expressed on muscle
mass during muscular atrophy and activated by FoxO family
of transcription factors, which remained inactivated by Akt
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phosphorylation [9, 36, 37, 40]. Besides the activity ofMuRF1
and MAFbx on muscle catabolism as an E3 ligase, these
genes are associated with the inhibition of the components
of muscular anabolism, such as a myogenic regulatory factor
and eIF3-f [42, 51].
Both genes seem to be increased in response to different
models of muscle atrophy (i.e., denervation and disuse)
[43]. In fact, in healthy subjects, for example, MAFbx and
MuRF1 expression (i.e., mRNA) has been found to remain
increased after the first 10 days of disuse atrophy in lower limb
biopsies [52, 53]. Data from experiments in animals deficient
in MAFbx and MuRF-1 (MAFbx−/− and MuRF-1−/−) genes
corroborate evidence about the role of both factors in muscle
atrophy, sinceMAFbx−/− andMuRF-1−/− animals show lower
magnitude of loss in muscle mass and fibers during atrophy
when compared to the wild type [43].
Although the results in healthy subjects demonstrate a
strong association between UPS, particularly MAFbx and
MuRF-1 activity, and muscle atrophy, evidence about post-
stroke patients are limited, and only data from animal studies
are available [47, 54].
In the experiment developed by Desgeorges et al. [47],
mice undergoing transient focal cerebral ischemia have
shown quadriceps, soleus, and tibialis anterior atrophy in
the paretic side. Concomitantly, the expression of MuRF-1
and MAFbx did increase in the paretic muscle. Data from
Springer et al. [54] corroborate these findings and show
increased proteasome activity in the muscle under atrophy
after transient focal cerebral ischemia [54].
Together with UPS, autophagy represents the two major
proteolytic systems in mammalian cells [55, 56]. Autophagy
may be characterized as a homeostatic process which controls
the degradation of damaged organelles, toxic proteins, and
intracellular pathogens [55, 56]. The extreme activity of the
autophagic complex is harmful to muscle mass, since up- and
downregulation of autophagic genes leads to muscle wasting
[55]. Regarding downregulation, atg7−/− mice, which present
autophagy inhibition, show degenerative changes in muscle
mass, lower myofiber size (∼40%), andmuscle strength when
compared to the controls, together with increased activity of
atrogenes (i.e., MuRF-1 and MAFbx), which can indicate a
relation between both factors [55, 56]. Furthermore, during
catabolic condition (i.e., fasting and denervation), inhibition
of autophagy increases the magnitude of muscle loss [55].
In poststroke patients, autophagy has been associated
withmuscle atrophy [47, 57]. However, these findings remain
controversial. In an animal model of stroke, the expression
of genes associated with autophagy complex (i.e., Ulk1, LC3,
and cathepsin L) was increased in paretic and nonparetic
limbs [47]. However, protein content did not follow the
expression of mRNA and remained unaltered. Yet according
to some researchers, the lack of changes in autophagy genes
does not rule out the association between the autophagic
complex and poststroke muscle atrophy, since a delayed
increase in proteins cannot be discarded [47]. In humans,
data from a number of studies seem to corroborate the
findings of Masiero et al. [55]. In fact, patients with chronic
spastic hemiplegia and visiblemuscle atrophy showdecreased
expression of autophagy genes when compared to healthy
older adults [57].
Myostatin has also been suggested as one of the main
pathways regulating muscle atrophy in poststroke patients
[47, 58]. Myostatin, also known as growth differentiation
factor 8 (GDF8), is key muscle protein regulator factor of
the transforming growth factor-𝛽 (TGF-𝛽) superfamily of
growth and differentiation factors [59, 60]. GDF8 seems to act
as a negative factor against muscle mass development from
embryogenesis to adult life, impairing muscle synthesis and
increasing muscle catabolism [59–61].
Data from observations in animal models knockout to
myostatin gene show that the mutant animal displayed from
two- to threefold more muscle mass when compared to
the control animals throughout life [61–63]. Although this
phenomenon is marked by an increased number of muscle
fibers (i.e., hyperplasia) during the first years of life, increase
in muscle cross-sectional area (i.e., hypertrophy) is predom-
inant in animals undergoing treatment with a myostatin
inhibitor (JA16) during adult life [61, 63]. In humans and in
cattle breeds, a mutation in the myostatin gene leads to its
downregulation, causing abnormal development of muscle
mass [64, 65].
Myostatin consists of two terminals: an N-terminal
propeptide, which inhibits the activity of myostatin, and a C-
terminal, which is the active form of the protein [60]. Before
activation, myostatin is secreted and remains in a latent form
[60]. Once activated, the activity of myostatin is regulated by
binding with the serine/threonine transmembrane receptor
[59, 60, 66]. After being activated by myostatin, the activin
type II receptor recruits, phosphorylates, and activates the
activin type I receptor, which is associated with SMAD pro-
teins [59, 60, 66]. These proteins are one of the mechanisms
responsible for the effect of myostatin on muscle cells, since
phosphorylated SMAD 2 and SMAD 3 build a complex with
SMAD 4, which is then translocated to the nucleus and
changes the transcription of target catabolic genes [59, 67].
Some researchers have also suggested that myostatin
may activate genes associated with UPS and maximize a
proteolytic process [68]. However, experiments did not show
the modulation of MuRF-1 and MAFbx by myostatin [68].
On the other hand,myostatin seems to inhibit the activity
of important factors associated with muscle protein synthesis
and regeneration, such as Akt, satellite cells and myogenic
factors (e.g., MyoD) [58, 67, 69, 70]. In fact, McCroskery
et al. [70] showed that myostatin knockout mice displayed
higher number of satellite cells activated in the cell cycle and
in steady state per unit of muscle fibers, together with faster
proliferation ofmyoblast when compared to the controls [70].
Myostatin was increased in some animal and human
models of muscle atrophy, for example, food deprivation,
muscle disuse, and muscle denervation [68, 69, 71, 72].
Moreover, gene electrotransfer of a myostatin expression
vector was found to induce 20% of muscle atrophy in tibialis
anterior muscle of rats [58].
It has been suggested that in poststroke patients, atro-
phy disuse and denervation would account for increased
myostatin. Moreover, myostatin is sensitive to glucocorti-
coids, which are highly consumed by poststroke patients [4].
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However, data remain controversial. In animals undergoing
transient focal cerebral ischemia, myostatin increases expo-
nentially in both paretic and nonparetic limb 3 days after
cerebral occlusion [47, 73]. However, SMAD 2 and SMAD
3 present downregulation [47]. The only study in humans,
to our knowledge, was performed by von Walden et al. [57].
They investigated atrophied lower limb muscle in patients
who suffered a stroke in the previous 9 years and found
that their biopsy presented lower myostatin expression when
compared to older healthy adults [57].
Thus, it is possible that myostatin modulates muscle
atrophy at the beginning of the phenomenon, but not during
its progression. These findings are corroborated by experi-
ments involving nonstroke patients, which demonstrated that
myostatin levels decrease few days after the beginning of
muscle atrophy, during the peak loss of muscle mass [58, 69].
In view of such a range of candidate mechanisms, it
is difficult to pinpoint the precise process responsible for
muscle atrophy in poststroke patients, despite the indica-
tions provided by the fact that some pathways (i.e., UPS,
autophagy, and myostatin) are increased during this process.
Furthermore, further studies involving both pathways in
animal models of stroke and in humans are needed, mainly
to understand the molecular signaling.
Figure 1 shows the anabolic and catabolic pathways indi-
cated to regulate muscle mass in poststroke patients.
4. Low-Grade Inflammation as
a Trigger Factor to Activation of
Muscle Atrophy Pathways
Inflammatory process is the mechanism of the immune
system in charge of protecting the organic system against
harmful agents and restoring homeostasis. Once activated,
the components of the immune system return to prestress
levels in few days or, at most, weeks. However, this is due
to the decreased capacity of the physiological organic system
to cope with stressful factors (e.g., reactive oxygen species
(ROS)), as may occur due to aging—leading to inflammatory
phenotype—or even in response to a pathological state,
leading to a chronic low-grade inflammation condition [74,
75].
A number of physiological disorders, such as chronic
pulmonary obstructive disease (CPOD), rheumatoid arthritis
(RA), cancer, and inflammatory myopathies, also called
myositis (i.e., polymyositis, inclusion body myositis, and
dermatomyositis), have been found to be associated with
elevated proinflammatory markers [8, 9, 76]. Furthermore,
inflammation has been suggested to be a common factor
leading to increased activity of atrophy-related catabolic
pathways, such as UPS and autophagy, during aging (i.e.,
senescence and senility) and in chronic degenerative states
(i.e., cachexia) [8, 9].
Animal studies have demonstrated the regulation of
proinflammatory cytokines in myoplasticity. Evidence in the
literature has shown that infusion of recombinant tumor
necrosis factor-alpha (TNF-𝛼) and TNF-𝛼 plus interleukin
type-1 (IL-1), both proinflammatory cytokines, increases
muscle catabolism in rats [77]. In mutant mice with overex-
pression of proinflammatory cytokines (i.e., interleukin type-
6 (IL-6)), muscle mass presents exacerbated atrophy when
compared to the wild type [78, 79]. However, inhibition of
IL-6 receptor prevents muscle wasting and increase in UPS
activity [79].
Inflammatory process may be also associated with the
muscle atrophy phenotype caused by cachexia syndrome
in some pathological conditions, since proinflammatory
cytokines expression (i.e., mRNA) and production are
increased in animalmodels of heart failure [80, 81] and cancer
cachexia [82].
Regarding human beings, cross-sectional studies have
found an association between increased concentrations of
proinflammatory cytokines (e.g., IL-6 and TNF-𝛼), their
soluble receptors, and acute phase proteins (i.e., C-reactive
protein (CRP)) and syndromes associated with low muscle
mass in elderly [83, 84], cancer cachexia [85], and chronic
heart failure [86]. Moreover, although not conclusive, a
number of longitudinal studies have suggested that high
concentrations of inflammatory markers may indicate a
higher degree of muscle atrophy after 3 years [87].
Between themyriad of cytokineswhichmay be associated
with muscle atrophy, TNF-𝛼 (also called cachectin) seems
to be the most likely candidate, due the high number of
catabolic pathways that its molecule are involved in [88]. In
fact, increased TNF-𝛼 is found inmuscle wasting related con-
ditions, such as cancer, heart failure, COPD, and sarcopenia
[83–86, 89].
However, in poststroke patients, this scenario remains
unclear. Indeed, the expression of mRNA TNF-𝛼 was
increased in the vastus lateralis muscle, contralateral to the
lesion, in chronic stroke survivors when compared to ipsilat-
eral limb [90]. Nevertheless, this result was not confirmed in
a more recent study [57]. Regarding systemic measurements,
an increased level of TNF-𝛼 in the serum and cerebrospinal
fluid was found in patients 24 hours, one week, and two
weeks after the stroke. These increases were associated with
infarct volume and severity of neurological impairment [91].
Corroborating these clinical findings, TNF-𝛼 blocking was
found to reduce the volume of infarction after occlusion of
the cerebral artery in mice [92].
Taken together, these data indicate a possible modulation
of TNF-𝛼 in the skeletal muscle and in the central nervous
system (e.g.,motor cortex), which in turn affects functionality
and, consequently, muscle mass (e.g., hemiparesis, spasticity,
rigidity, balance, and coordination changes).
TNF-𝛼 effects on muscle wasting my be said to be due
to inhibition of protein synthesis (because of alterations in
the levels of anabolic hormones, such as IGF-1), a result
of phosphorylation of IRS-1 and IRS-2 receptors, inhibition
of satellite cells activity, and reduction of MyoD expression
[88, 93–95]. Moreover, TNF-𝛼 seems to downregulate the
synthesis of myosin heavy chain of slow-twitch fibers and
increase their degradation [96, 97], which may account for
the changes in fiber phenotype in the muscles of chronic
stroke survivors.
Regarding proteolysis, we may hypothesize that the pro-
cess is mediated by TNF-𝛼 through direct (e.g., apoptosis)
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Figure 1: Anabolic and catabolic pathways regulating muscle mass. P = phosphorylation; Ub = ubiquitin.
and indirect mechanisms [88]. The indirect mechanisms
are based on the capacity to recruit other proinflammatory
cytokines and immune system cells, particularly by the stimu-
lus to cause nuclear factor kappa-light-chain-enhancer ofNF-
𝜅B activation [88, 96, 98]. In this sense, some researchers have
suggested that muscle atrophy mediated by TNF-𝛼/NF-𝜅B
activitymay be themost powerful stimulus tomuscle atrophy
[18, 19].
NF-𝜅B is a molecular signaling pathway originating from
an evolutionary process, which plays a critical role in the
activity of the immune system, regulating some physiological
and pathological process, increasing the levels of inducible
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nitric oxide (iNOS), with subsequent formation of reactive
oxygen species, which results in oxidative damage [99].
Moreover, given its capacity to increase proinflammatory
cytokines synthesis, NF-𝜅B is known as the master regulator
of inflammatory state [99, 100].
NF-𝜅Bmay be activated by some stimulus, such as proin-
flammatory cytokines and ROS [96, 99–102]. However, when
not activated, NF-𝜅B remains in the cytoplasm, inhibited
by I𝜅B𝛼 activity, a molecule from I𝜅B kinase (IKK) fam-
ily [100, 102]. However, due to stimulation, another IKK
molecule, I𝜅B𝛽 (IKK), phosphorylates and activates I𝜅B𝛼,
leading to its ubiquitination and eventually to the degradation
on 26S proteasome [100, 102]. Since I𝜅B𝛼 acts by inhibiting
the activity of NF-𝜅B, degradation makes NF-𝜅B free to
translocate to the nucleus and change the gene transcription
of proinflammatory cytokines [100, 102]. Regarding TNF-
𝛼, NF-𝜅B activation by this proinflammatory cytokine is
mediated through 1 TNF-𝛼 receptor (TNFR1) and/or 2 TNF-
𝛼 receptor (TNFR2) [88].
Data from literature points to the capacity of NF-𝜅B to
contribute to muscle atrophy, since this molecule is increased
in different models of muscle atrophy, that is, disuse and can-
cer cachexia [100]. Besides, in a seminal study, Cai et al. [100]
have developed transgenic mice with NF-𝜅B overexpression
and found severe muscle atrophy in these animals, due to a
sharp decrease in the cross-sectional area of muscle fibers,
when compared to thewild type. Interestingly, this phenotype
was followed by increased MuRF-1 and proteasome activity,
indicating a possible interaction between NF-𝜅B and UPS.
Moreover, when the authors blockedNF-𝜅B,musclemasswas
restored [100].
In view of these findings, it is possible to infer that
NF-𝜅B activation by NF-𝜅B in poststroke patients may
contribute not only to muscle atrophy, but also to endothelial
dysfunction, causing a positive feedback, ROS production,
and inflammation, while maintaining NF-𝜅B activation.This
phenotype has been already suggested for other pathological
states, such as diabetes mellitus type II [99]. However,
data concerning poststroke patients remain unclear in the
literature.
Myosteatosis is another condition found in the paretic
limb of poststroke patients.This condition is characterized by
fat deposition in the skeletal muscle, as well as by the amount
of fat mass around the muscle. Evidence in literature suggests
that myosteatosis is increased in the atrophied paretic limb
in poststroke patients, when compared to the ipsilateral
limb [103, 104]. The differences in intramuscular fat content
between contralateral and ipsilateral limb can reach 48% in
favor of the impaired limb [20]. This may account for the
larger increase in fatmass relative tomuscle area in the paretic
limb relative to ipsilateral limb [20, 73, 103].
The white adipose tissue (WAT) is not just a deposit of
triacylglycerol and, consequently, energy but also an active
endocrine organ capable of synthesizing and secreting proin-
flammatory cytokines [85, 105–109]. Increased expression
and protein content of proinflammatory cytokines are found
in syndromes related withmuscle wasting, as cancer cachexia
[85, 105–110].
Indeed, visceral (i.e., mesenteric, epididymal, and
retroperitoneal) and subcutaneous WAT in cancer cachexia
present increased expression of proinflammatory cytokines
(i.e., TNF-𝛼, IL-6, and IL-1𝛽), acute phase proteins (i.e.,
C-reactive protein (CRP)), and chemotaxis factors (i.e.,
monocyte chemoattractant protein-1 (MCP-1)), concomitant
to increased NF-𝜅Bp65, IKK-𝛼, and toll-like receptor 2
(TLR2) expression [85, 105, 106, 109, 110]. Moreover, cancer
patients with cachexia have a lower number of macrophages
(M𝜙) with an anti-inflammatory phenotype (M2) when
compared to weight-stable cancer patients, and this may be
associated with fat deposition [110].
However, data showing an association between muscle
atrophy and WAT in patients with cachexia should be care-
fully extrapolated to poststroke patients, since data so far have
indicated that proinflammatory phenotype may be tumor-
dependent [106, 110]. On the other hand, muscle skeletal
remodeling is also observed during aging, and older adults
show up 2.5-fold more myosteatosis than young adults [111,
112]. Interestingly, intramuscular fat infiltration is negatively
associated with muscle volumes of 15 muscles of the lower
limbs in the elderly [112], which points to a strong associ-
ation between myosteatosis and muscle atrophy. Moreover,
intramuscular fat infiltration is associated with increased
expression of proinflammatory cytokines (i.e., IL-6) [113].
Thus, wemay hypothesize that the increasedmyosteatosis
observed in poststroke patients is associated with muscle
atrophy due a low-grade inflammatory state, possibly mod-
ulated by NF-𝜅B activity. Moreover, some researchers have
found that peroxisome proliferator activated receptor (PPAR)
may contribute to myosteatosis, leading to muscle atrophy
[114].
PPAR is a member of a nuclear receptor family of
ligand-dependent transcriptions factors and comprises 3
PPAR subtypes: PPAR𝛼 (NR1C1), PPAR𝛽/𝛿 (NR1C2), and
PPAR𝛾 (NR1C3), which have wide range of effects in the
physiological system [114–116].
Themain activity of PPAR is located in the adipose tissue,
where this molecule regulates positively (i.e., upregulation)
the network of adiposity-specific genes, controlling lipid
metabolism (i.e., adipogenesis), adipocyte differentiation
(i.e., white and brown), and glucose homeostasis (i.e., insulin
sensitivity) [114, 115, 117].
Moreover, recent evidence has suggested that PPAR may
have an anti-inflammatory propriety, inhibiting inflamma-
tory mediators, such as cytokines (i.e., IL-6 and TNF-𝛼),
adhesion molecules (vascular adhesion protein 1 (VCAM1)),
acute phase proteins (CRP), IKK, andNF-𝜅B [114–117].More-
over, PPAR may counterregulate inflammatory conditions
induced by pathological states (i.e., obesity and liver fibrosis)
[115]. Besides, PPAR may contribute to increasing insulin
sensitivity, through adiponectin synthesis [117].
However, inflammatory cytokines, such as TNF-𝛼, may
inhibit PPAR, leading to a wide range of alterations, con-
tributing to impaired glucose metabolism, hyperinsulinemia,
ROS production, and possibly atherosclerosis, along with
increased inflammatory state [114]. Thus, decrease in PPAR
activity may lead to a catabolic environment associated with
muscle atrophy. Nonetheless, the role of NF-𝜅B activity and
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PPAR𝛾 in themuscle atrophy of poststroke patients should be
further studied and tested.
Interestingly, the increase in intramuscular fat content
in poststroke patients has also been widely suggested as a
trigger factor to impaired glucose metabolism, a condition
that may reach about 80% of the chronic stroke patients
[73, 103, 118]. In fact, increased intramuscular fat infiltra-
tion, regardless of visceral fat, contributes to the genesis of
dyslipidemia, and impaired insulin sensitivity and glucose
uptake, causing hyperinsulinemia and hyperglycemia, thus
providing a favorable environment for chronic conditions,
such as hypertension and diabetes mellitus type II [103, 104,
118, 119]. Therefore, PPAR maybe the pathway underlying
impaired glucosemetabolism due to increased intramuscular
fat content in poststroke patients.
Figure 2 shows the inflammatory factors indicated to
regulate muscle atrophy in poststroke patients.
5. Physical Exercise and Stroke
As aforementioned, poststroke patients are generally affected
by morphofunctional and cognitive complications, which
impairs their capacity to perform the daily life activity and
basic and advanced self-care, leading to sedentary behavior
and increased hospitalization.
On the other hand, physical exercise (PE) has been
postulated by international organizations (i.e., American
Heart Association (AHA) and American Stroke Association
(ASA)) as a useful tool for the rehabilitation of poststroke
patients, since PE may counterregulate the most of the
deleterious effects of stroke in the organic systems [10].
Indeed, several reviews have pointed out that PE can elicit
improvement in cognition, upper and lower limb motor
function, cardiovascular performance, cardiovascular risk
factors (e.g., triglycerides), fatigue resistance, balance, gait,
and mobility [10, 12, 120].
Most studies on the role of PE in poststroke patients
have focused on aerobic exercise. A recent systematic review
showed that most clinical trials studying the effect of aerobic
physical exercise on stroke patients have used short-term
interventions (6–8 weeks), with a mean frequency of 3
sessions per week, and a 30–40-minute exercise duration
[120]. Regarding exercise intensity, moderate and progressive
(moderate to moderate-intense) intensities prevailed [120].
Increase in cardiorespiratory fitness (15–18%) is the most
cited alteration after moderate aerobic exercise, and it occurs
even after short-term exercise protocols (i.e., 8 weeks) [10,
120–123]. However, the beneficial effects of moderate aerobic
exercise in poststroke patients are not restricted to cardiores-
piratory fitness, and studies have demonstrated increase in
mobility (e.g., get up and go test (GUG)) andmotor function,
[123], as well as decrease in cardiovascular risk factors, such
as hyperinsulinemia [122].
Changes in the cognitive domain after moderate aerobic
exercise have also been the focus of some studies. In the
experiment of Quaney et al. [123], the authors did not
observe significant changes in selective attention, resistance
to interference, working memory, and learning after 8 weeks
of moderate aerobic exercise (70% of HRmax), which com-
prised 45m sessions. A recent meta-analytic review [124]
has challenged those findings, arguing that the practice of
physical exercise is able to improve cognition in poststroke
patients, even when patients presented depressive symptoms
and high anxiety levels [124]. However, these findings should
be carefully evaluated since notmany studies have focused on
cognitive improvements, and these were generally assessed
as a secondary outcome. Also, cognitive assessment would
require more specific methodological tools.
Some studies have dealt with outcomes that are not gen-
erally investigated as clinical outcomes but are nevertheless
useful to understanding the phenomenon associated with
stroke and the impact of physical exercise on this condition.
Ivey et al. [121], for example, have studied the effects of PE
on blood flow in poststroke patients. Impaired blood flow is
usually associated with endothelium dysfunction, ROS, and
inflammation, posing a risk factor to myocardial infarction
and recurrent stroke. After 6 months of moderate intensity
aerobic exercise (60–70% HR reserve), volunteers showed
significant increase in rest blood flow, 25% and 23% in paretic
and nonparetic limb and in reactive hyperemia blood flow,
25% and 22% in paretic and nonparetic limb [121].
Some researchers have argued that although aerobic
exercises may have beneficial effects on poststroke patients,
theywould be poorly tolerated in this population [125]. In this
context, resistance training exercises have been suggested as
an interesting alternative, since they are easier to modulate
than aerobic exercise and as such more manageable for
poststroke patients [12, 125]. Also, resistance training is able
to elicit increase in physical function (i.e., muscle strength
and power) and mobility [126, 127]. Nevertheless, resistance
training has been poorly studied and the outcomes assessed
are generally restricted to physical function. Further studies
are required to evaluate other important outcomes, such as
improved cognition [125].
Interestingly, few studies aimed to record the effects of
PE on muscle mass. Regarding aerobic exercise, Ivey et al.
[122] have undertaken one of the few studies investigating
this issue, but they did not observe significant alterations. In
relation to resistance exercise, Ryan et al. [73] developed the
only study that reported the effects of this kind of intervention
on muscle mass in poststroke patients. Other researchers
have concentrated on the effects of resistance training on
myostatin expression. Their findings demonstrated that 12
weeks of resistance exercise until muscle failure was able to
elicit an increase inmusclemass of the paretic limb (13%) and
nonparetic limb (9%) [73]. A decrease of 49% of myostatin
mRNA on paretic limb and 27% on the nonparetic limb was
also reported [73].
The rather limited number of studies in the literature
dealing with the effects of physical exercise on muscle mass
makes it difficult to offer a well-informed assessment of the
effects of physical exercise on muscle mass. More studies
on this association are required, since muscle atrophy and
sarcopenia are linked to hemodynamic [128–130], metabolic
[131], and functional alterations [132, 133], which contribute to
poor outcomes in poststroke patients. Additionally, increase
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Figure 2: Influence of the inflammatory factors in the regulation of muscle mass.
in muscle mass is associated with increase in physical func-
tion and mobility [134–136].
6. The Anti-Inflammatory Effects of Physical
Exercise and the Role of Myokines
Physical exercise has been indicated as a powerful non-
pharmacological therapy to decrease inflammatory markers,
ameliorate the anti-inflammatory environment, and, conse-
quently, lower chronic inflammation in several diseases (e.g.,
chronic pulmonary obstructive disease, atherosclerosis, heart
failure, and myocardial infarction) [13–16, 137].
In fact, it has been found that chronic moderate and
moderate-to-high intensity physical exercise may elicit a
decrease in inflammatory factors (e.g., TNF-𝛼, IL-1𝛽, IL-
6, intercellular adhesion molecule (CAM-1), acute phase
proteins (CRP), vascular cell adhesion molecule (VCAM-
1), and granulocyte-macrophage colony-stimulating factor
(GM-CSF)), in different animal models of diseases, such as
heart failure [80], myocardial infarction [138], and cancer
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cachexia-anorexia [139] in healthy [140] and senescent ani-
mals [141], as well as in human patients with moderate to
severe chronic heart failure (∼24% ejection fraction) [142],
overweight and obesity [143, 144], diabetes mellitus [143–
150], myopathies (i.e., dermatomyositis and polymyositis),
rheumatoid arthritis [148], spinal cord injury [149], and
systemic lupus erythematosus [151], and in elderly people:
those with chronical conditions [150] and the healthy [152].
These alterations can occur locally, affecting the expres-
sion of these factors in the cardiac muscle [138], skeletal
muscle [80, 140, 146, 147, 150], and adipose tissue [153], in the
central nervous system [139, 141] or systemically [142–145, 151,
152]. Furthermore, PE also seems to be effective in increasing
anti-inflammatory markers (e.g., IL-10) [80, 107]. Besides,
data from literature indicate that alterations in inflammatory
factors may also be associated with improved physiological
function (e.g., ventricular function; aerobic capacity; insulin
resistance) [138, 142, 143, 154].
There are no evidences about the effects of chronic phys-
ical exercise on the inflammatory markers in stroke patients.
Besides being associated with muscle atrophy and poor
prognosis, high inflammatory markers have been linked to
elevated risk of recurrent ischemic stroke and cardiovascular
events even after adjustment for age, sex, race, comorbidities,
and statin use [155].
Several mechanisms may be associated with the anti-
inflammatory effects of physical exercise: decrease in
the expression of toll-like receptors on monocytes and
macrophages, inhibition of the infiltration of immune cells
on adipose tissue, changes in the phenotype of macrophages
on adipose tissue, and decrease in adipose tissue [13].
For many years, the skeletal muscle was predominantly
known by its capacity to generate strength, power, and, conse-
quently, physical movement. Later, researchers hypothesized
that some or a single humoral factor would be secreted by
the active skeletal muscle and would act by altering the
signalization of different molecular pathways [14, 137]. As
knowledge about the activity and the properties of these
molecules was scarce, they were initially called “exercise
factor,” “work stimulus,” and “work factor” [14, 137].
However, accumulated evidence now views the skeletal
muscle acting as an active endocrine organ, since the con-
traction of skeletal muscle in response to a determined load,
as observed during physical exercise, may elicit synthesis and
release of peptides, hormone-like factors and cytokines—
pro- and anti-inflammatory—which, in turn, alter the func-
tioning of tissues and organs [13–15, 137, 156]. Once aggre-
gated, these molecules are termed myokines, and they have
been found to be responsible for the interaction between the
skeletal muscle and the organic system, due to their action
in a paracrine and endocrine and, possibly, autocrine fashion
[14, 156].
Regarding the anti-inflammatory effects of the myokines,
interleukin-6 (IL-6) is one of the most well-known and
studied, being the first to be denominated as a myokine
[13, 15, 137, 157]. Besides, IL-6 is considered one of the key
myokines which provide the anti-inflammatory effects of
physical exercise [13, 15, 137].
Several studies in human beings have demonstrated an
increase by over 100-fold in IL-6 levels, as well as mRNA
expression, during and after PE, independently of exercise-
induced muscle damage and inflammation [158–160]. More-
over, IL-6 is not just an anti-inflammatory cytokine, but
evidences indicate its action on glucose metabolism and
bioavailability, contributing to beta-oxidation and glucose
uptake [160, 161].
In relation to physical exercise, IL-6 seems to be sen-
sitive to alterations on the variables of PE, since running
intensity and volume are positively associated with IL-6 levels
on plasma [159, 160, 162]. In humans, moderate aerobic
physical exercise (75%VO
2max) and rhIL-6 infusion are able
to increase IL-6 levels in blood plasma and, concomitantly,
attenuate the increase in TNF-𝛼 levels after endotoxin infu-
sion [163]. Also, IL-6 plasma levels decreased after cessa-
tion of PE or rhIL-6 infusion [158, 159, 162]. Interestingly,
cessation of low-levels of rhIL-6 infusion was accompanied
by a decrease in anti-inflammatory cytokines: IL-1 receptor
antagonist (IL-1ra) and IL-10 [159]. On the other hand,
decreased IL-6 levels were found 1,5 h after the end of a
strenuous physical exercise, showing a sharp increase (>100x)
after the end of exercise session. This was accompanied by
IL-1ra values 45-fold higher than preexercise levels, which, in
turn, were positively correlated with IL-6 levels [162].
Therefore, these data indicate that the anti-inflammatory
effect of physical exercise can be mediated by myokines,
mainly IL-6.However, there is not a consensus onwhether IL-
6 acts directly or through other anti-inflammatory cytokines
(IL-1ra, IL-10). Both theories are plausible, and the fact
remains thatmyokines do contribute to an anti-inflammatory
environment. Additionally, other myokines, IL-8, IL-15, and
the brain derived neurotrophic factor (BDNF), have been
linked to angiogenesis, metabolism, neurogenesis, andmem-
ory formation [14, 137, 161]. But their effect on inflammatory
state have yet to be elucidated.
Therefore, these data indicate that the anti-inflammatory
effect of physical exercise may be mediated by myokines,
mainly IL-6. However, these myokines have not been studied
in a stroke context and inferences are therefore limited.
Nevertheless, increase in myokines and decrease in the
inflammatory milieu of poststroke patients after physical
exercise may improve the prognosis of this population, due
to a better physiological environment, one which increases
muscle mass, strength, power, and mobility while decreasing
cardiovascular risk factors.
Figure 3 shows a schematic representation of the
myokines activation in response to physical exercise and its
inhibitory anti-inflammatory activity on the inflammatory
environment.
7. Cholinergic Anti-Inflammatory Pathway
Findings from studies conducted by Tracey group [164–166],
as well as from other groups [138, 167, 168], have suggested
that the central nervous system (CNS) may act by regulating
the central and peripheral inflammatory process [164–166].
This phenomenon occurs due to the activity of the two
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functional divisions of the autonomous (also called visceral)
nervous system—sympathetic (SNS) and parasympathetic
nervous system (PNS)—so that each would regulate in a
different fashion the immune system and, consequently, the
inflammatory process [165, 166, 169].
SNC is known to be activated during “flight or fight” con-
ditions, since it offers the organic system a large blood supply
(i.e., increased heart rate and blood pressure), energy sub-
strate (i.e., increased lipolysis), oxygen supply (i.e., bronchial
dilation), visual acuity, adrenalin and noradrenalin con-
centrations, and muscle strength (which could help with
survival during Paleolithic and Neolithic period [169].) SNC
is increased during situations of allostasis (e.g., hypotension
and electrolyte imbalance in order to reestablish the normal
functioning).Moreover, this system also acts during dynamic
homeostasis, helping to control several physiological systems
(e.g., gastrointestinal, cardiovascular, and endocrinal) [165,
166].
Catecholamines (adrenalin and noradrenalin) are synthe-
sized and secreted by the adrenalmedulla in the adrenal gland
in response to sympathetic activity. Their role in immune
cells lies in the fact that they alter their functioning by the
modulation of cytokine release, since these cells have 𝛼 and 𝛽
receptors to catecholamines [165].
In turn, PNS acts in an anti-inflammatory fashion, a
phenomenon denominated cholinergic anti-inflammatory
pathway (CAIP) [164–166, 169–173]. The vagus nerve is an
inherent component of this pathway.This nerve is the decimal
(X) nerve of the SNC and has afferent, motor, and effer-
ent projections [174]. Regarding afferent projections, these
conduct information from sensitive periphery receptors, as
chemoreceptors, baroreceptors, and visceral receptors on the
thorax and abdomen to the CNS [174].
Concerning CAIP, the afferent vagus nerve fibers act as
a peripheral sensory component of the PNS and identify the
increase in proinflammatory cytokines from the inflamma-
tion, linking the CNS to the immune system [164–166, 169–
173].
In the brain, the vagus nerve is found in the nodose
ganglion and inside the dorsal vagal complex of the medulla
oblongata, which is formed by the nucleus of the solitary
tract (NST), dorsal motor nucleus of the vagus, and the
area postrema [174]. From there, a neurohumoral and a
cholinergic pathway can occur and counterbalance inflam-
mation [174]. The neurohumoral pathway is activated due
to the synapse of the NTS with the paraventricular nucleus,
a hypothalamic nucleus, which stimulates the synthesis and
release of the corticotropin releasing hormone (CRH) [174].
However, the functioning of this pathway remains poorly
understood.
On the other hand, projections from the NTS form the
efferent arc of the inflammatory reflex, which would act
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through efferent vagus nerve fibers and neurotransmitters
[169]. In summary, CAIP occurs after the inflammatory
signalization on the afferent vagus nerve fibers to the NTS;
a reflex response mediated by efferent vagus nerve fibers
will propagate and culminate in acetylcholine (i.e., ACh), the
mainly parasympathetic neurotransmitter, release [165, 166,
169].
Several studies have demonstrated the protective effect
of CAIP stimulation, as well as the need of the efferent
vagus nerve, on animal models of systemic inflammation
[164, 168, 175–177]. In fact, results from experimental studies
have found that intravenous (IV) and intracerebroventric-
ular (ICV) pretreatment with CNI-1493 (a pharmacological
stimulator of the vagus nerve), carbachol (a cholinergic ago-
nist), pyridostigmine (a peripheral cholinesterase inhibitor
agent), and electrical stimulation protected rats against
inflammatory factors associated with acute hypovolemic
hemorrhagic shock, endotoxin-induced shock, myocardial
infarction, and carrageenan-induced acute inflammation,
such as increase in serum TNF-𝛼 levels, edema, neutrophil
aggregation, macrophage infiltration, NF-𝜅B protein levels,
and loss of IkBa [164, 168, 175–177]. Also, these alterations on
inflammatory markers may be associated with increased M2
macrophages, which are characterized by producing mainly
anti-inflammatory cytokines and regulatory T cells (Tregs),
known by their immunosuppressive capacity [168].
On the other hand, surgical and chemical (i.e., atrophin,
an antagonist of cholinergic pathway) vagotomy eliminated
the protective effects of chemical and electrical vagus nerve
stimulation on inflammatory markers [164]. Furthermore,
after surgical vagotomy, the researchers performed new
electrical stimulation, but this time on the distal end of the
transected right vagus nerve and found an attenuation of the
acute inflammation [176].
The activity of CAIP seems to bemediated by ACh, which
is the most important neurotransmitter, being the main neu-
rotransmitter release in postganglionic efferent vagal neurons
[165, 166, 172]. After the activation of central muscarinic
receptor M1 and/or inhibition of the negative regulator of
the ACh release (the M2 receptor), ACh is released and acts
by using two G protein-coupled receptors, muscarinic and
nicotinic [169, 170].
Classically, the most well-known activity of ACh in the
organic system is mediating muscarinic receptors, which are
found in the hearth and neurons and in the smooth muscle,
for example. However, regarding the immunological activity
of the ACh, the muscarinic receptor did not seem to have
a role in this response. A specific unit of nicotinic recep-
tors, nicotinic acetylcholine receptor 𝛼7-subunit (𝛼7nAChR),
is found in immune cells and, once activated, it inhibits
cytokine secretion [178, 179]. In fact, Wang et al. [179] have
demonstrated that 𝛼7nAChR is essential to the effectiveness
of the anti-inflammatory effect of the cholinergic efferent arc
on TNF-𝛼, IL-1𝛽, and IL-6 concentration in endotoxemic
rats, since 𝛼7nAChR-deficient mice present higher TNF-𝛼,
IL-𝛽, and IL-6 concentrations when compared to the wild
type [179].
Furthermore, increased ACh levels, due to activation and
inhibition of M1 and M2 muscarinic receptors, respectively,
and consequently increase in vagus nerve activity (as demon-
strated by Pavlov et al. [170]) will cause inhibitory effects on
inflammatory markers (i.e., TNF-𝛼, IL-1B, IL-6, and IL-18)
through a posttranscriptional mechanism, since ACh did not
alter proinflammatory cytokines mRNA in LPS-stimulated
macrophage [170, 176].
In relation to stroke patients, evidences in the literature
have been indicating that poststroke patients present a phe-
notype of dysautonomia, mainly characterized by decreased
on vagal tonus [11, 180, 181]. Indeed, cross-sectional studies
showed impairment of the autonomic control, diagnosed by
decreased parasympathetic activity in time domain measures
(i.e., rootmean square of successive differences (RMSSD) and
standard deviation of the normal-to-normal R-R intervals
(SDNN)) and frequency domains (high frequency (HF)) of
HRV—in right-sided and left-sided ischemic stroke patients
when compared to aged-matched healthy control [11, 180,
181]. Also, these results aremore evident in patients with right
insular involvement, probably due to the association with
cardiac control [180].
Besides its negative impact on cardiovascular compli-
cations (e.g., increase in ventricular and supraventricular
arrhythmias) [11, 180, 181], dysautonomia may be one of the
mechanisms responsible for the aforementioned increased
inflammatory markers observed locally and systematically
in poststroke patients, due to impairment in the CAIP
functioning.
Interestingly, CAIP was thought at first to act only as
an arc reflex, controlling acutely the inflammatory state
and preventing cellular damage [169, 173]. However, some
researchers have suggested that CAIP may also act in a
chronic fashion, in the pharmacological treatment, and it
may be responsible for the anti-inflammatory effects of
physical exercise, for example [154, 182]. However, only few
experiments have tested this hypothesis [138, 183].
In the research undertaken by Conti et al. [183], the
authors tested the hypothesis that physical exercise would
positively modulate the deleterious effects of menopause,
mimicked through ovariectomy, on autonomic nervous sys-
tem and inflammatory profile in metabolic syndrome (i.e.,
SHR more fructose diet) female rats. Animal underwent
8 weeks of low-to moderate intensity combined physical
exercise, aerobic (60% maximal running speed) plus resis-
tance training (60% of the maximum load), which was
performed 5 days per week. Results showed that combined
physical exercise was able to restore dysautonomia and TNF-
𝛼 levels on cardiac tissue. Furthermore, oxidative stress,
one of the mechanisms associated with NF-𝜅B activation,
was decreased in both cardiac and renal tissue of trained
metabolic syndrome female rats when compared to sedentary
metabolic syndrome rats [183].
Rodrigues et al. [138] have studied the effect of PE
on autonomic control and the potential impact on inflam-
matory markers in infarcted rats. In this study, infarcted
rats underwent a moderate intensity (50–70 of the VO
2max)
exercise program, 1 h per day, 5 days per week, during 3
months. Researchers observed increased HF of the pulse
interval, which characterizes parasympathetic activity, in
trained group when compared to the sedentary infarcted
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control group. Moreover, TNF-𝛼 concentration and TNF-
𝛼/IL-10 ratio were lower in trained infarcted rats than in
sedentary control. Interestingly, one group of rats trained
for only two months, followed by a 1-month detraining
period. Results of this group were similar to the trained
group, presenting increased parasympathetic activity and
lower inflammatory profile when compared to the infarcted
group. Also, in the same study, the researchers found that
CAIP was a plausible candidate mechanism associated with
decreased inflammatory profile, since HF was negatively
correlated with IL-6 and TNF-𝛼 concentration on the left
ventricle [138].
Unfortunately, the effects of physical exercise on cardio-
vascular autonomic control and their impact on tissue and
systemic inflammation profile remain poorly understood and
further studies focusing on this issue are needed. However,
recent studies have been demonstrated that direct cortical
vagus nerve stimulation (Cvns) and indirect (noninvasive
transcutaneous vagus nerve stimulation (nVNS)) vagal nerve
stimulation lead to decreased infarct volume (up to 33%),
neurological damage, and increased grip strength in rats
undergoing acute cerebral ischemia [184, 185]. Furthermore,
experiments have shown that the middle cerebral artery
occlusion (MCAO) animal model undergoing vagal nerve
stimulation presented lower Iba1 and CD68 (microglial
markers indicating immune response of brain tissue) and
TNF-𝛼, IL-6, and IL-1𝛽 concentrations than sham-control
[184, 185].
Taken together, data on the anti-inflammatory effect of
physical exercise on the inflammatory markers in animal
models of myocardial infarction and menopause and the
effectiveness of electrical stimulation of vagus nerves in
decreasing inflammation inMCAO animals, make it possible
to infer that physical exercisemay activate CAIP in poststroke
patients and, consequently, contribute to a decrease in inflam-
matory markers, allowing recovery of the organic system.
Figure 3 shows a schematic representation of the CAIP
activation in response to physical exercise, and its inhibitory
anti-inflammatory activity on the inflammatory environ-
ment.
8. Conclusion
We presented several findings from a range of studies which
may indicate that proinflammatory markers (e.g., TNF-𝛼
and IL-6) may be responsible for the activation of pathways
associated with muscle atrophy in poststroke patients (e.g.,
UPS system). On the other hand, physical exercise seems to
be a powerful tool to counterbalancing these phenomena, due
its capacity to elicit a decrease in inflammatory markers in
different animal models of disease (e.g., cancer, myocardial
infarction, and heart failure), as well as in human beings.
These beneficial outcomes may take place because physi-
cal exercises seem to act in an anti-inflammatory fashion,
through myokines and the cholinergic anti-inflammatory
pathway. Even if these data are mostly inference-based, they
may point to the possible mechanism to be further studied
and encourage research on inflammation andmuscle atrophy
and on the effect of physical exercise in poststroke patients.
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MAFbx: Muscle atrophy F-box
MuRF1: Muscle ringer finger 1
nVNS: Noninvasive transcutaneous vagus nerve
stimulation
NF-𝜅B: Nuclear factor kappa-light-chain-enhancer of
activated B
PNS: Parasympathetic nervous system
PI3K: Phosphatidylinositol 3-kinase
ROS: Reactive oxygen species
Tregs: Regulatory T cells
RA: Rheumatoid arthritis
RMSSD: Root mean square of successive differences
6MWT: Six-minute walk test
SDNN: Standard deviation of the normal-to-normal
R-R intervals
SNS: Sympathetic nervous system
TLR2: Toll-like receptor 2
TGF-𝛽: Transforming growth factor-𝛽
TNF-𝛼: Tumor necrosis factor-alpha
UPS: Ubiquitin proteasome system
VCAM1: Vascular adhesion protein 1
WAT: White adipose tissue.
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